Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
出版年份 2021 全文链接
标题
Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
作者
关键词
-
出版物
Frontiers in Cardiovascular Medicine
Volume 8, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-11-17
DOI
10.3389/fcvm.2021.789931
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation
- (2021) Minyoung Oh et al. MEDICINE
- The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD
- (2021) Foluso Agboola et al. Journal of Managed Care & Specialty Pharmacy
- Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1
- (2020) Ulf Landmesser et al. CARDIOVASCULAR RESEARCH
- Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression
- (2020) Walter Masson et al. Lipids in Health and Disease
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Review of Bempedoic Acid: A New Drug for an Old Problem
- (2020) Dat Nguyen et al. ANNALS OF PHARMACOTHERAPY
- Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy
- (2020) Prakash Deedwania et al. JAMA Cardiology
- Cost-Effectiveness of Alirocumab
- (2019) Dhruv S. Kazi et al. ANNALS OF INTERNAL MEDICINE
- Statin Toxicity
- (2019) Natalie C. Ward et al. CIRCULATION RESEARCH
- Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
- (2019) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- How Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner
- (2019) Rhanderson Cardoso et al. MAYO CLINIC PROCEEDINGS
- Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance
- (2019) Ulrich Laufs et al. Journal of the American Heart Association
- Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease
- (2019) Sabina A. Murphy et al. JAMA Cardiology
- Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial
- (2019) David M. Charytan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy
- (2019) Christie M Ballantyne et al. European Journal of Preventive Cardiology
- PCSK9 and inflammation: a review of experimental and clinical evidence
- (2019) Amir Abbas Momtazi-Borojeni et al. European Heart Journal-Cardiovascular Pharmacotherapy
- Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control
- (2019) Antonio J. Vallejo-Vaz et al. ATHEROSCLEROSIS
- Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome ― The ODYSSEY J-IVUS Trial ―
- (2019) Junya Ako et al. CIRCULATION JOURNAL
- Statins and the potential for higher diabetes mellitus risk
- (2019) Srikanth Yandrapalli et al. Expert Review of Clinical Pharmacology
- Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease
- (2019) Anne C. Goldberg et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Inclisiran—New hope in the management of lipid disorders?
- (2019) Krzysztof Dyrbuś et al. Journal of Clinical Lipidology
- Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies
- (2019) R. Scott Wright et al. MAYO CLINIC PROCEEDINGS
- PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes
- (2018) Connie N. Hess et al. Annual Review of Medicine
- Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
- (2018) Christie M. Ballantyne et al. ATHEROSCLEROSIS
- Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials
- (2018) Dean J. Kereiakes et al. ATHEROSCLEROSIS
- Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
- (2018) Sreeneeranj Kasichayanula et al. CLINICAL PHARMACOKINETICS
- Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels
- (2018) Marc S. Sabatine et al. JAMA Cardiology
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
- (2018) Scott M. Grundy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Alirocumab Reduces Fatal and Nonfatal Cardiovascular Events
- (2018) Michael Szarek et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study
- (2017) Shinichi Oikawa et al. Journal of Atherosclerosis and Thrombosis
- Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention
- (2017) Erin A. Bohula et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cognitive Function in a Randomized Trial of Evolocumab
- (2017) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers
- (2017) Alejandro Arrieta et al. JAMA Cardiology
- Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease
- (2017) Christopher P. Cannon et al. JAMA Cardiology
- Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
- (2017) Marc P. Bonaca et al. CIRCULATION
- Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus
- (2017) Robert P. Giugliano et al. CIRCULATION
- Alirocumab: A Review in Hypercholesterolemia
- (2016) Sarah L. Greig et al. American Journal of Cardiovascular Drugs
- A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I
- (2016) Eli M. Roth et al. ATHEROSCLEROSIS
- Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase
- (2016) Ozlem Bilen et al. Current Atherosclerosis Reports
- No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
- (2016) Helen M. Colhoun et al. EUROPEAN HEART JOURNAL
- Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
- (2016) Dhruv S. Kazi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
- (2016) Donald M. Lloyd-Jones et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
- (2016) Stephen L. Pinkosky et al. Nature Communications
- Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies
- (2016) Jacques Rey et al. Journal of the American Heart Association
- Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
- (2015) Xin-Lin Zhang et al. BMC Medicine
- Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes
- (2015) Traci Turner et al. CLINICAL THERAPEUTICS
- Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
- (2015) Patrick M. Moriarty et al. Journal of Clinical Lipidology
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial
- (2014) Eli M. Roth et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
- (2014) Erik Stroes et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Anti-PCSK9 Monotherapy for Hypercholesterolemia
- (2014) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
- (2014) Dirk J. Blom et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
- (2013) Neil J. Stone et al. CIRCULATION
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients
- (2012) David Sullivan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
- (2012) Evan A. Stein et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
- (2011) Colin Baigent et al. LANCET
- Cost Effectiveness of Ezetimibe in Patients with Cardiovascular Disease and Statin Intolerance or Contraindications
- (2009) Roberta Ara et al. American Journal of Cardiovascular Drugs
- Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials
- (2008) A. Pandor et al. JOURNAL OF INTERNAL MEDICINE
- Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
- (2008) Anne B. Rossebø et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analyses of Cancer Data from Three Ezetimibe Trials
- (2008) Richard Peto et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now